GlassScriptPhysician profile
Zehra Farzal
NPI 1396109856
$19,868.67
in general payments reported to CMS, 2019-2025
18 companies · $5,503 in 2025
The $5,503 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.54 · 2020: $4,274 · 2021: $5,234 · 2022: $591 · 2023: $473 · 2024: $3,738 · 2025: $5,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772 · Travel and Lodging: $2,873 · Consulting Fee: $2,720 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,772.06 |
| Travel and Lodging | $2,873.08 |
| Consulting Fee | $2,720.00 |
| Education | $348.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,361.80 | 2021-2024 | Vercise |
| Merz Pharmaceuticals, LLC | $4,343.22 | 2021-2025 | Xeomin, Inbrija |
| Medtronic USA, INC. | $4,000.00 | 2020 | |
| Medtronic, INC. | $1,560.27 | 2021-2025 | Percept PC Brainsense |
| Acadia Pharmaceuticals INC | $893.74 | 2020-2025 | Nuplazid |
| Abbvie INC. | $787.78 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $431.36 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $388.65 | 2023-2025 | Austedo Xr |
| Allergan, INC. | $366.11 | 2019-2021 | |
| Abbott Laboratories | $341.77 | 2021-2025 | Infinity |
| Kyowa Kirin, INC. | $337.00 | 2021-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $250.08 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $249.81 | 2019-2024 | Crexont |
| Supernus Pharmaceuticals, INC. | $213.50 | 2023-2025 | Qelbree |
| Insightec,INC | $167.55 | 2025 | Exablate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $93.57 | 2020-2023 | Inbrija |
| Adamas Pharmaceuticals, INC. | $82.46 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zehra Farzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.